Top Markets
#1 Astar Astar +17.19%
#2 Hive Hive +11.38%
#3 Steem Steem +10.25%
#4 PondCoin PondCoin +9.51%
#5 MiL.k Alliance MiL.k Alliance +8.83%
#6 Threshold Network Threshold Network +6.94%
#7 Cap Cap +5.44%
#8 Clearpool Clearpool +5.17%
#9 BORA BORA +4.80%
#10 Polymesh Polymesh +4.75%
Coin of the day
Astar Astar
Settings
Language
ENGLISH
Currency
USD
Theme
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Rank in Stocks #170
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily... Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Share Price
$519.38
Last synced: 2026-09-14
Market Cap
$131.82B
Change (1 day)
0.76%
Change (1 year)
32.09%
Country
US
Trade Vertex Pharmaceuticals Incorporated (VRTX)

Category

Healthcare
Number of shares outstanding for Vertex Pharmaceuticals Incorporated (VRTX)
Number of shares outstanding as of June 2026: 253.90M
According to Vertex Pharmaceuticals Incorporated latest financial reports and stock price the company's current number of shares outstanding is 253.90M. At the end of December 2024 the company had 257.50M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Vertex Pharmaceuticals Incorporated (VRTX) from 2000 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 253.90M -0.70%
2025 255.70M -0.70%
2024 257.50M -0.08%
2023 257.70M 0.62%
2022 256.10M -0.62%
2021 257.70M -0.82%
2020 259.84M 1.21%
2019 256.73M 0.96%
2018 254.29M 2.18%
2017 248.86M 2.16%
2016 243.59M 1.14%
2015 240.84M 2.52%
2014 234.92M 4.49%
2013 224.83M 6.08%
2012 211.95M 3.44%
2011 204.89M 2.24%
2010 200.40M 15.67%
2009 173.26M 23.27%
2008 140.56M 8.97%
2007 128.99M 13.92%
2006 113.22M 26.87%
2005 89.24M 13.58%
2004 78.57M 2.03%
2003 77.00M 1.66%
2002 75.75M 1.73%
2001 74.46M 10.02%
2000 67.68M 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -75.51%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 88.62%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 55.97%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0.00 -100.00%
BE